Reviva Pharmaceuticals Holdings, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$4.17 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-30
- Reviva Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$4.17M.
- Reviva Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$6.28M.
- Reviva Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$8.22M.
- Reviva Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$5.93M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$4.17M 10-K · filed 2026-03-30 | |
| 2024-12-31 | -$6.28M 10-K · filed 2026-03-30 | |
| 2023-12-31 | -$8.22M 10-K · filed 2025-04-03 | |
| 2022-12-31 | -$5.93M 10-K · filed 2024-04-15 | -$5.10M 10-K · filed 2023-03-30 |
| 2021-12-31 | -$1.79M 10-K · filed 2023-03-30 | |
| 2020-12-31 | -$794.34K 10-K · filed 2022-03-15 | |
| 2019-12-31 | -$177.56K 10-K/A · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |